6CK2
Insulin analog containing a YB26W mutation
6CK2 の概要
| エントリーDOI | 10.2210/pdb6ck2/pdb |
| 分子名称 | Insulin A chain, Insulin B chain, ZINC ION, ... (6 entities in total) |
| 機能のキーワード | long-acting, basal, therapeutic, peptide hormone, diabetes, biomolecular engineering, hormone |
| 由来する生物種 | Homo sapiens (Human) 詳細 |
| タンパク質・核酸の鎖数 | 4 |
| 化学式量合計 | 11911.69 |
| 構造登録者 | |
| 主引用文献 | Rege, N.K.,Wickramasinghe, N.P.,Tustan, A.N.,Phillips, N.F.B.,Yee, V.C.,Ismail-Beigi, F.,Weiss, M.A. Structure-based stabilization of insulin as a therapeutic protein assembly via enhanced aromatic-aromatic interactions. J. Biol. Chem., 293:10895-10910, 2018 Cited by PubMed Abstract: Key contributions to protein structure and stability are provided by weakly polar interactions, which arise from asymmetric electronic distributions within amino acids and peptide bonds. Of particular interest are aromatic side chains whose directional π-systems commonly stabilize protein interiors and interfaces. Here, we consider aromatic-aromatic interactions within a model protein assembly: the dimer interface of insulin. Semi-classical simulations of aromatic-aromatic interactions at this interface suggested that substitution of residue Tyr by Trp would preserve native structure while enhancing dimerization (and hence hexamer stability). The crystal structure of a [Trp]insulin analog (determined as a TR zinc hexamer at a resolution of 2.25 Å) was observed to be essentially identical to that of WT insulin. Remarkably and yet in general accordance with theoretical expectations, spectroscopic studies demonstrated a 150-fold increase in the lifetime of the variant hexamer, a critical pharmacokinetic parameter influencing design of long-acting formulations. Functional studies in diabetic rats indeed revealed prolonged action following subcutaneous injection. The potency of the Trp-modified analog was equal to or greater than an unmodified control. Thus, exploiting a general quantum-chemical feature of protein structure and stability, our results exemplify a mechanism-based approach to the optimization of a therapeutic protein assembly. PubMed: 29880646DOI: 10.1074/jbc.RA118.003650 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.25 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






